Age-Related Macular Degeneration market growth

The Age-Related Macular Degeneration market report also offers comprehensive insights into the Age-Related Macular Degeneration market size, share, Age-Related Macular Degeneration epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Age-Related Macular Degeneration market size growth forward.

Some of the key highlights from the Age-Related Macular Degeneration Market Insights Report:

• Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Age-Related Macular Degeneration treatment outlook.

• In January 2025, Astellas Pharma announced that the U.S. FDA had accepted the Class 1 resubmission of the supplemental New Drug Application (sNDA) for IZERVAY, a treatment targeting geographic atrophy related to age-related macular degeneration.

• The market size for Age-related Macular Degeneration (AMD) in seven major markets is divided into two categories: Dry-AMD and Wet-AMD. In 2021, the total AMD market size was estimated at approximately USD 9,840 million and is projected to grow by 2034. Specifically, the market size for Dry-AMD was around USD 1,377 million, while Wet-AMD accounted for approximately USD 8,463 million, both of which are expected to expand further by 2034.

• In 2021, the total number of prevalent Age-related Macular Degeneration (AMD) cases in the seven major markets (7MM) was approximately 51,743,361. This figure is projected to grow at a compound annual growth rate (CAGR) of 1.6% by 2034. In the United States, there were around 17,282,569 prevalent cases of AMD in 2021.

• Among the EU5 countries, Germany had the highest number of AMD cases, with 7,850,793 cases in 2021, followed by France. Japan accounted for approximately 21% of AMD prevalent cases within the 7MM during the same year.

• The total diagnosed AMD cases in 2021 across the 7MM were approximately 38,807,521, with the United States reporting the highest number of diagnosed cases.

• Type-specific analysis revealed approximately 3,880,752 cases of Wet-AMD and 34,926,768 cases of Dry-AMD in the 7MM in 2021. These numbers are expected to increase significantly by 2034.

• The anticipated launch of new therapies, along with an increasing number of diagnosed AMD cases, is likely to drive market growth in the coming years. Emerging treatments such as OPT-302, KSI-301, RGX-314, AKST4290, and others hold significant potential to positively impact the Wet-AMD market size.

• As per DelveInsight analysis, the Age-Related Macular Degeneration market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Age-Related Macular Degeneration Market Landscape

Age-Related Macular Degeneration Overview

Age-related Macular Degeneration (AMD) is the leading cause of blindness among elderly individuals in developed countries. This eye condition progressively affects the central vision required for tasks such as driving, reading, recognizing faces, and perceiving colors. As AMD advances, it results in the loss of central vision, leaving many patients unable to perform activities involving color and detail, significantly reducing their quality of life. While the exact mechanisms underlying AMD are not fully understood, advancements in genetic technology have identified various polymorphisms uniquely associated with the disease.

AMD is marked by the gradual degeneration of the macula, the central portion of the retina, leading to central vision loss. Clinically, it is categorized into early, intermediate, or late stages, based on features such as drusen, pigmentation abnormalities, retinal pigment epithelium (RPE) atrophy, and exudative choroidal neovascularization (CNV).

Additionally, AMD can be classified into two forms: dry (atrophic or non-neovascular) and wet (exudative or neovascular).

Do you know the treatment paradigms for different countries? Download our Age-Related Macular Degeneration Market Sample Report

Age-Related Macular Degeneration Epidemiology Segmentation

DelveInsight’s Age-Related Macular Degeneration market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Age-Related Macular Degeneration historical patient pools and forecasted Age-Related Macular Degeneration patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Age-Related Macular Degeneration Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

• Age-Related Macular Degeneration Prevalence

• Age-Specific Age-Related Macular Degeneration Prevalence

• Gender-Specific Age-Related Macular Degeneration Prevalence

• Diagnosed and Treatable Cases of Age-Related Macular Degeneration

Visit for more @ Age-Related Macular Degeneration Epidemiological Insights

Age-Related Macular Degeneration Market OutlookAge-related Macular Degeneration (AMD) is a chronic, progressive disease of the central retina and the leading cause of irreversible blindness in the Western world and Asia-Pacific regions. Globally, approximately 8.7% of the population is affected by AMD. The wet form of the disease accounts for over 90% of severe central visual acuity (VA) loss associated with AMD.

Wet AMD Market Outlook:

The introduction of anti-VEGF intravitreal injections has revolutionized wet AMD treatment by effectively halting its pathophysiological progression, restoring retinal morphology, and preserving its function. Over the years, anti-VEGF injections have become the standard of care, outperforming earlier treatments like photodynamic therapy (PDT) and laser photocoagulation. Current therapies such as Lucentis (ranibizumab), Eylea (aflibercept), and Avastin (bevacizumab) effectively resolve exudative signs in most patients. Additionally, Faricimab and Susvimo have recently received approval for wet AMD management.

Dry AMD Market Outlook:

Currently, no approved therapies are available for dry AMD, leaving a significant unmet need for treatments to slow disease progression. The pathophysiology of dry AMD remains poorly understood, and the advanced stage of the disease may contribute to challenges in achieving primary outcomes rather than a lack of action on specific therapeutic targets. DelveInsight’s market analysis excludes other treatment options such as procedures and lifestyle management, focusing solely on pharmacological approaches for market size estimation in the 7MM.

Age-Related Macular Degeneration Marketed Drugs

• Eylea (aflibercept): Regeneron Pharmaceuticals

• Beovu (brolucizumab): Novartis

• Lucentis (ranibizumab): Roche

Age-Related Macular Degeneration Emerging Drugs

• OPT-302: Opthea Limited

• KSI-301: Kodiak Sciences Inc.

• RGX-314: Regenxbio

• Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca

• EG-301: Evergreen Therapeutics

Age-Related Macular Degeneration Key Companies

• Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others

For more information, visit Age-Related Macular Degeneration Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Age-Related Macular Degeneration Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Age-Related Macular Degeneration, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Age-Related Macular Degeneration epidemiology in the 7MM

• Age-Related Macular Degeneration marketed and emerging therapies

• Age-Related Macular Degeneration companies

• Age-Related Macular Degeneration market drivers and barriers

Table of Contents:

1 Age-Related Macular Degeneration Market Key Comprehensive Insights

2 Age-Related Macular Degeneration Market Report Introduction

3 Competitive Intelligence Analysis for Age-Related Macular Degeneration

4 Age-Related Macular Degeneration Market Analysis Overview at a Glance

5 Executive Summary of Age-Related Macular Degeneration

6 Age-Related Macular Degeneration Epidemiology and Market Methodology

7 Age-Related Macular Degeneration Epidemiology and Patient Population

8 Age-Related Macular Degeneration Patient Journey

9 Age-Related Macular Degeneration Treatment Algorithm, Age-Related Macular Degeneration Current Treatment, and Medical Practices

10 Key Endpoints in Age-Related Macular Degeneration Clinical Trials

11 Age-Related Macular Degeneration Marketed Therapies

12 Age-Related Macular Degeneration Emerging Therapies

13 Age-Related Macular Degeneration: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Age-Related Macular Degeneration

16 Age-Related Macular Degeneration Market Key Opinion Leaders Reviews

18 Age-Related Macular Degeneration Market Drivers

19 Age-Related Macular Degeneration Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Age-Related Macular Degeneration Epidemiology 2034

DelveInsight’s “Age-Related Macular Degeneration – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Age-Related Macular Degeneration epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Age-Related Macular Degeneration Pipeline 2024

“Age-Related Macular Degeneration Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Age-Related Macular Degeneration market. A detailed picture of the Age-Related Macular Degeneration pipeline landscape is provided, which includes the disease overview and Age-Related Macular Degeneration treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/